Chester County News and Community Website
WILMINGTON, DE — AstraZeneca named Rick R. Suarez senior vice president, U.S. president and head of its U.S. BioPharmaceuticals business, putting a longtime company executive in charge of a sweeping …
AstraZeneca Taps Rick Suarez to Lead $50B U.S. Expansion Push Read More WILMINGTON, DE — AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) said their jointly developed breast cancer therapy ENHERTU has received Breakthrough Therapy Designation from the U.S. Food and Drug …
ENHERTU Scores Tenth FDA Fast-Track as Breast Cancer Data Shifts Playbook Read More WILMINGTON, DE — AstraZeneca PLC (NASDAQ: AZN) and Japan’s Daiichi Sankyo said the U.S. Food and Drug Administration has approved ENHERTU in combination with pertuzumab as a first-line treatment for …
FDA Clears ENHERTU Combo as First-Line Breakthrough in HER2 Breast Cancer Read More WILMINGTON, DE — AstraZeneca plc (Nasdaq: AZN) is sharply expanding its ambitions in hematology and cell therapy, unveiling new clinical data across blood cancers as it makes its largest-ever showing …
AstraZeneca Unveils Sweeping Blood Cancer Push With Record ASH Presence Read More WILMINGTON, DE — AstraZeneca secured U.S. approval for its IMFINZI (durvalumab) regimen in combination with FLOT chemotherapy for early-stage and locally advanced gastric and gastroesophageal junction cancers, marking the first …
AstraZeneca Wins Landmark Approval for IMFINZI Regimen in Early Gastric Cancer Read More
WILMINGTON, DE — AstraZeneca (NASDAQ: AZN) announced plans to invest $2 billion to expand its manufacturing footprint in Maryland, marking the company’s fourth major U.S. commitment this year and advancing …
AstraZeneca’s $2 Billion Maryland Expansion Raises Big Questions for U.S. Biotech Read More WILMINGTON, DE — AstraZeneca reported statistically significant Phase III results showing that Fasenra (benralizumab) can substantially delay disease worsening for patients with hypereosinophilic syndrome (HES), a rare and potentially life-threatening …
AstraZeneca’s Fasenra Shows Major Breakthrough in Delaying HES Disease Flares Read More WILMINGTON, DE — In a major advance for breast cancer treatment, AstraZeneca and Daiichi Sankyo announced that their drug DATROWAY (datopotamab deruxtecan-dlnk) extended the lives of patients with metastatic triple-negative …
Breakthrough Drug Shows Unprecedented Survival Gains in Aggressive Breast Cancer Read More WILMINGTON, DE — AstraZeneca and Daiichi Sankyo reported breakthrough results from the Phase III DESTINY-Breast05 trial, showing that their drug ENHERTU (fam-trastuzumab deruxtecan-nxki) cut the risk of disease recurrence or …
AstraZeneca’s Enhertu Slashes Breast Cancer Recurrence Risk in Landmark Trial Read More WILMINGTON, DE — AstraZeneca and Daiichi Sankyo reported that their antibody-drug conjugate ENHERTU® (fam-trastuzumab deruxtecan-nxki), when used before surgery and followed by standard therapy, achieved a pathologic complete response in …
ENHERTU Combination Shows Promising Results in Early Breast Cancer Trial Read More